The immune response crucially determines the survival of patients with malignant tumors including breast carcinoma. The aim of the present study was to evaluate retrospectively an association of peripheral blood cell count (PBC)-derived ratios and urinary neopterin concentration with prognosis in breast cancer patients. Urinary neopterin, neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR) and platelet-to-lymphocyte ratio (PLR) were retrospectively analyzed in a cohort of 474 breast cancer patients. NLR and PLR correlated positively with each other and negatively with LMR, but no correlation between neopterin concentrations and PBC-derived ratios was observed. Increased urinary neopterin concentration was a significant predictor of poor survival in patients with active disease, but PLR, NLR or LMR were not significantly associated with survival in multivariate analysis. In conclusion, increased urinary neopterin was a significant predictor of poor survival in patients with breast cancer and active disease.
Introduction
The estimation of patient prognosis is an essential component of the determination of therapeutic strategy and management of cancer patients. Prognostic assessment helps to select appropriate measures or to avoid unnecessary therapy. In addition, some prognostic biomarkers also predict the response to therapy. Thus, predictive and prognostic biomarkers currently play an important role in the management of cancer patients [1] . While most attention so far has been focused on biomarkers associated with the properties of tumor cell, the prognostic and predictive significance of inflammatory reaction associated with the host response to neoplastic growth is being increasingly recognized [2] .
Several biomarkers of the inflammatory response have been introduced into the management of cancer patients over the last decades, including neopterin. Urinary or serum neopterin concentrations are increased in a wide range of disorders as diverse as cancer, viral infections, autoimmune disorders, organ rejection or atherosclerosis and its complications [3] [4] [5] [6] [7] [8] [9] [10] . An association between high neopterin concentrations and poor prognosis has been reported in patients with different primary tumors [6, [11] [12] [13] [14] . In the last few years we have witnessed the advent of composite biomarkers that can be obtained by calculating the ratios of lymphocytes to other components of peripheral blood [15] . It has been shown that the neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR) and platelet-to-lymphocyte ratio (PLR) are independent prognostic biomarkers across a spectrum of solid tumor types [16] [17] [18] [19] [20] . Because peripheral blood cell count (PBC) is measured routinely in all cancer patients, many retrospective studies on large patient cohorts have been reported.
The cure rate of patients with breast cancer is high and many patients die of causes other than breast cancer. Complications of atherosclerosis represent the most common competitive cause of death in patients with breast cancer. Similarly to cancer, atherosclerosis is associated with inflammatory response, and it was demonstrated that neopterin as well as PBC-derived ratios are associated with biomarkers of atherosclerosis or its complications and also predict the risk of atherosclerosis-related events [21] [22] [23] [24] [25] [26] [27] [28] . However, only limited information is available on the association between PBC-derived ratios and other biomarkers of inflammatory response [29, 30] .
The aim of the present study was to retrospectively evaluate the association of urinary neopterin and PBCderived ratios with long-term prognosis in a large cohort of patients with breast cancer.
Patients and methods
NLR, LMR and PLR were calculated in a cohort of 474 patients with histologically verified breast cancer treated and followed at Charles University Medical School and Teaching Hospital, Hradec Králové, Czech Republic in whom urinary neopterin was evaluated. Prognostic significance of urinary neopterin in part of this cohort after a shorter follow-up has been reported earlier [12] . The survival information was updated for this study. Patients with a history of breast cancer were investigated at different time points (settings) during the course of the disease. Most patients (n = 288) were investigated before the start of any therapy (surgical or medical). Other settings included patients after local therapy before the start of systemic adjuvant therapy (n = 48), previously treated patients before the start of systemic therapy for metachronous recurrent or metastatic disease (n = 24), during the course of treatment for recurrent or metastatic disease (n = 14), during adjuvant hormonal therapy (n = 86), or during the course of follow-up without any antitumor therapy (n = 14). The presence of active disease that was defined as either tumor before the start of any treatment or under therapy (e.g. for recurrent disease) in the absence of radical surgery or radiotherapy, and stage were also recorded. Among all 474 patients, 320 patients had active disease, and 154 patients had no evidence of disease activity at the time of examination, and, at the time of examination, 53 patients had evidence of metastatic disease while 421 patients had no evidence of metastases. Patients with metastatic disease included treatmentnaïve patients with synchronous metastases, previously treated patients examined before the start of systemic therapy for metachronous metastatic disease and patients investigated during the course of treatment for metastatic disease. The present analysis was part of a project approved by the institutional Ethical Committee. Methods used to analyze urinary neopterin and PBC have been described earlier [12, 31] . Manual differential count was obtained in all patients.
Correlations were analyzed using Spearman's rank correlation coefficient (r s ). Survival was assessed using the Kaplan-Meier method and log-rank test in the case of univariate analysis. Cox regression was used for multivariate survival analysis with the results expressed as hazard ratios (HR) and 95% confidence intervals (CI). In order to test the differences in survival probability with the log-rank test also for continuous variables, including urinary neopterin and PBCderived ratios, a cut-off point was determined using the minimum Wald p-value method [32, 33] . The decision on statistical significance was based on p = 0.05 level. The analyses were performed using SAS/ STAT ® 9.3 software (SAS Institute Inc., Cary, NC, USA).
Results
Patients with metastatic disease and examined during adjuvant hormonal therapy were significantly older. Compared to patients examined before the start of any therapy urinary neopterin was significantly higher in patients studied after the treatment of primary tumor (before the start of systemic adjuvant therapy), in patients evaluated before the treatment for metachronous metastases and in patients examined during adjuvant hormonal therapy (Table 1) . Urinary neopterin concentrations in patients examined during the course of follow-up were significantly lower compared to patients after treatment of primary tumor (p = 0.005), patients studied before the treatment for metachronous metastases (p = 0.003) and patients evaluated during adjuvant hormonal therapy (p = 0.002). PBC-derived ratios did not exhibit significant differences in these subgroups of patients (Table 1) . Patients with active disease had significantly higher neopterin concentrations compared to patients with no evidence of disease activity. Patients with metastatic disease had higher NLR. An increase of urinary neopterin of borderline statistical significance was also observed in patients with metastatic disease (Table 2 ). The correlations of PBC-derived ratios and urinary neopterin are shown in Table 3 . NLR and PLR correlated positively with each other and negatively with LMR. No Shown is the mean±standard deviation of the investigated parameters in different subgroups of patients outlined in patients and methods. Significant differences are highlighted by bold type.
significant correlation was observed between PBC-derived ratios and urinary neopterin.
At the time of analysis, 141 patients in this cohort died and 333 were alive, with the median follow-up of surviving patients in this cohort being 104 months. In the univariate analysis of the whole cohort of 474 patients, the presence of metastasis (p < 0.0001), the presence of active disease (p < 0.0001), age ≥ 57 years (p < 0.0001), stage (p < 0.0001), tumor type (p = 0.011), urinary neopterin ≥ 181 μmol/mol creatinine (p = 0.0022), LMR < 1.5 (p = 0.0071) and NLR ≥ 1.5 (p = 0.0184) were significant predictors of poor survival, but PLR was not significantly associated with survival. In the multivariate analysis of the whole cohort, stratified according to the setting, age (evaluated as continuous variable; HR = 1.040; 95% CI 1.020-1.060; p < 0.0001), tumor stage (Table 4 ) and triple negative phenotype (HR 1.954; 95% CI 1.148, 3.325; p = 0.0136 compared to luminal phenotype) were significant predictors of survival.
Among 288 patients investigated before the start of therapy, age ≥ 59 years (p = 0.0002), urinary neopterin ≥ 238 μmol/mol creatinine (p < 0.0001; Figure 1 ), LMR < 6.6 (p = 0.0374) and stage (p < 0.0001) were significant predictors of poor survival, but neither NLR nor PLR were significantly associated with survival in the univariate analysis. In the multivariate analysis stratified according the stage, only age (HR = 1.034; 95% CI 1.011-1.058; p = 0.0035) and urinary neopterin (HR = 1.002; 95% CI 1.001-1.004; p = 0.0038), both evaluated as continuous variables, were significant predictors of survival.
In 154 patients without active disease, age < 67 years (p < 0.0001), stage (p < 0.0001) and urinary neopterin < 202 μmol/mol creatinine (p = 0.0053) were significant predictors of survival while in 320 patients with active disease age ≥ 57 years (p = 0.0001), urinary neopterin ≥ 181 μmol/mol creatinine (p = 0.004), NLR ≥ 4.2 (p = 0.0047), and stage (p < 0.0001) were significant predictors of poor survival. In multivariate analysis, only age evaluated as a continuous variable (HR = 1.075; 95% CI 1.025-1.127; p = 0.0029) was significantly associated with survival stratified according to the stage in patients without active disease while urinary neopterin (HR = 1.002; 95% CI 1.000-1.004; p = 0.0127), any prior therapy (HR = 2.249; 95% CI 1.031-4.906; p = 0.0417) and age (HR = 1.029; 95% CI 1.005-1.053; p = 0.0166) predicted survival when stratified according to the stage in patients with active disease.
In 421 patients without evidence of distant metastases, age < 59 years (p = 0.0001), urinary neopterin < 250 μmol/mol creatinine (p < 0.0001), LMR ≥ 6.8 (p = 0.0243) and stage (p < 0.0001) were significant predictors of survival in univariate analysis. In multivariate analysis stratified according the tumor type, only age (HR = 1.043; 95% Shown is the mean±standard deviation of the investigated parameters in different subgroups of patients outlined in patients and methods. NED no evidence of disease. Significant differences are indicated by bold type. Spearman's rank correlation coefficients between urinary neopterin concentrations and PBC-derived ratios with p-values and number of subjects indicated. Significant correlations are highlighted with bold type. 
Discussion
As previously reported in different cohorts of patients with a history of breast cancer and controls [25] , urinary neopterin concentrations did not correlate with PBC-derived ratios. The present data confirm that increased urinary neopterin is associated with inferior survival. Although PBC-derived ratios were associated with prognosis in the univariate analysis, this could not be confirmed in multivariate analysis in any of the subgroups. In contrast, increased neopterin concentrations were independently associated with poor prognosis in multivariate analysis in patients examined before the start of therapy and in patients with active disease. As expected, urinary neopterin concentrations were significantly increased in patients with active disease, and a trend of higher neopterin was observed in patients with distant metastases. The differences observed among the patients investigated in different settings may also reflect sometimes significant differences in age among these subgroups. A significant correlation was observed between age and urinary neopterin concentrations. Association with age could explain higher neopterin concentrations in patients treated in the adjuvant setting.
Numerous retrospective studies have reported prognostic significance of PBC-derived ratios in patients with different primary tumors as well as with non-neoplastic disorders [16-20, 22-26, 28, 34] . Concentrations of neopterin in the urine or serum represent a biomarker associated with different primary tumors as well as with atherosclerosis [3, 4, 6, 11, 21, 35, 36] . In cancer patients negative prognostic significance of increased neopterin concentrations has been reported in different primary tumors [6, [11] [12] [13] 35] .
Changes in PBC-derived ratios are observed in a similar range of disorders as in the case of neopterin [16] [17] [18] [19] [20] [22] [23] [24] [25] [26] [27] [28] . Moreover, a correlation between NLR and CRP has been noted in patients with cancer [30] or complications of atherosclerosis [37] . Because both PBC-derived ratios and neopterin concentrations reflect inflammatory response associated with the host response against neoplasia, it could be expected that significant correlations would be observed between NLR, LMR or PLR and urinary neopterin. Contrary to these expectations, no correlation between neopterin concentrations and PBC-derived ratios was observed despite the fact that a large cohort of patients was investigated indicating that neopterin and PBC-derived ratios are independent biomarkers of inflammatory response.
Moreover, in contrast to PBC-derived ratios, high urinary neopterin concentrations were an independent predictor of survival in patients examined before the start of therapy or patients with active disease. The observation of independent prognostic significance of urinary neopterin concentrations confirms and refines, after a longer follow-up, the findings obtained in the same cohort of patients [12] . Interestingly, neopterin concentration was an independent predictor of prognosis only in patients who had active disease, either before the start of therapy or were under treatment for recurrent disease. In patients with no evidence of disease activity, the association of neopterin was not evident, possibly because of the low number of events in this subgroups and because these events were more likely to be associated with competing causes of death.
The lack of correlation between neopterin and PBCderived ratios may suggest that neopterin and PBC-derived ratios could be combined in indices of inflammatory activity. However, in the present retrospective analyses, different PBC-derived ratios were significant predictors of survival in univariate analyses in different subgroups of patients, but none of these biomarkers was significant in multivariate analysis. Based on the results of the present retrospective analysis urinary neopterin appears to represent a biomarker superior to any of the three PBC-derived ratios examined, but these results should be confirmed in a prospective study.
Both early diagnosis and improved systemic therapy are thought to contribute to the improved outcome of patients with breast cancer. However, it is evident that the administration of systemic therapy may result in the acceleration of atherosclerosis [38] . Inflammatory response associated with cancer or induced by therapy may contribute to the progression of atherosclerosis in breast cancer patients [39] . From this perspective, the nonspecific nature of neopterin and PBC-derived ratios is an advantage in patients with breast cancer as it covers both of the two fundamental competitive causes of death in this population, cancer and atherosclerosis with its complications.
The present study has obviously limitations. The analysis on a rather heterogeneous cohort of patients was retrospective and should therefore be regarded as hypothesis-generating. Neopterin as well as PBC-derived ratios reflect systemic immune and inflammatory phenomena, but crucial for the outcome of the host-tumor interaction may be the tumor microenvironment that is more difficult to assess [40, 41] .
In conclusion, no correlation was observed between urinary neopterin concentrations and any of the PBCderived ratios. In the present cohort, increased urinary neopterin was an independent predictor of poor survival in patients with active disease, in contrast to PBC-derived ratios.
